Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.

EQT Healthcare Growth is a new buy-out strategy that builds on EQT’s 30-year healthcare track record, focused on scaling innovative, fast-growing healthcare companies to help deliver positive outcomes across the value chain. By helping companies build commercial muscle and expand their global reach, the strategy aims to enable the development of medical research, diagnostics, tools and treatments to deliver more efficient and accessible healthcare.

Mabtech is a category leading provider of tests and kits for studying immune responses predominantly in vaccine, infectious diseases, and oncology research. The company is based in Sweden and has over 900 customers in more than 60 countries. EQT Healthcare Growth will support Mabtech as it looks to expand its scale and reach.

The transaction is subject to customary conditions and approvals and is expected to close in Q1 2024.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Robin Sultani and Filip Magnusson (M&A), Stojan Arnerstål and Rebecka Målquist (IPR), Louise Brorsson Salomon, Helena Göransson, Kamyar Najmi and August Ahlin (Financing), Christoffer Nordin and Rebecka Danelius Gedin (Agreements and Permits), Mika Jordan and Elis Allmark (IT), Nicklas Thorgerzon and Lisa Hörnqvist (GDPR), Gulestan Ali (Employment), Kristoffer Larson (Real Estate), Mia Falk, Sam Fakhraie Ardekani and Maja Höglund (Compliance and Sanctions), Sebastian Örndahl, Daniel Wendelsson, Dagne Sabockis, Lovisa Lewin and Hilda Ivarson (Regulatory) and Gabriella Balbo (Transaction Support Coordinator).

Related

Vinge advises Pricer in connection with Vusion’s public takeover offer

On 17 November 2026, VusionGroup S.A., a French public limited company listed on Euronext Paris, announced a recommended public takeover offer to the shareholders of Pricer Aktiebolag (publ) to acquire all shares in Pricer for a consideration of SEK 6.00 per share. The offer values all shares in Pricer at approximately SEK 980.4 million.
November 20, 2026

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026